Asleep at the Switch
This article was originally published in RPM Report
Executive Summary
Drug reviews by FDA don't always go smoothly. In the case of Neurocrine Biosciences, things got really bumpy when implementation of an electronic NDA filing system came as the drug center was reorganizing its review divisions. Neurocrine says both factored into the delay of its investigational sleep agent indiplon.